Imagion Biosystems Limited (Company) is committed to the objective of promoting investor confidence and the rights of shareholders.
Read the Imagion Biosystems Limited Disclosure and Communication Policy.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance